DIRECT BRAIN ADMINISTRATION OF CHEMOTHERAPEUTICS TO THE CSF FOR PATIENTS WITH PRIMARY AND SECONDARY BRAIN TUMORS

摘要

In some embodiments, a method may include treating brain cancer sensitive to cytotoxic effect. The method may include intraventricularly administering to a subject via a subject's cerebrospinal fluid an effective amount of a pharmaceutical formulation. The pharmaceutical formulation may include at least one chemical compound. In some embodiments, the pharmaceutical formulation may include at least one aqueous diluent. The at least one chemical compound may include a molecular weight of between about 400 MW and about 10,0000 MW. The at least one chemical compound may include protein binding of greater than 30% and greater than 70 Angstroms in cross sectional area. In some embodiments, the at least one chemical compound includes Irinotecan, SN-38, and/or a related derivative thereof. In some embodiments, the method may include ameliorating and/or inhibiting brain cancer in the subject using the pharmaceutical formulation.